SCHEMBL5766321

SCHEMBL5766321

CN(C)CC#Cc1ccc([N+](=O)[O-])c(N)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAPT P10636 4/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
CYP2A6 P11509 1/20 0.40
RECQL P46063 1/20 0.39
SIRT6 Q8N6T7 1/20 0.39
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
TBK1 Q9UHD2 1/20 0.36
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16654173 0.89 MEN1 (0.48) TSHRTDP1MAPTALDH1A1LMNA
SCHEMBL1063282 0.81 TDP1 (0.50) TSHRTDP1MAPTALDH1A1LMNA
SCHEMBL10025485 0.81 MAPT (0.43) MAPTALDH1A1LMNACYP2A6POLB
SCHEMBL18789074 0.79 TDP1 (0.59) TSHRTDP1MAPTALDH1A1LMNA
SCHEMBL18780686 0.77 MAPT (0.46) TSHRTDP1MAPTALDH1A1LMNA
SCHEMBL20982691 0.76 MAPT (0.60) TSHRTDP1MAPTALDH1A1LMNA
SCHEMBL378545 0.75 PYCR1 (0.46) TSHRTDP1MAPTALDH1A1CYP2A6
SCHEMBL20982677 0.75 ALDH1A1 (0.46) TSHRTDP1MAPTALDH1A1LMNA
SCHEMBL8293278 0.75 TDP1 (0.50) TSHRTDP1MAPTALDH1A1LMNA
SCHEMBL1068908 0.75 TDP1 (0.50) TSHRTDP1MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
EP-1663953-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-06-07 EP disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005030705-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 TSHR 3869/4885TDP1 926/4885MAPT 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.